Outcome of Living Donor Liver Transplantation in Patients with HCV related Hepatocellular Carcinoma

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, accounting for about 1 million related deaths annually. An estimated 372, 000 new cases of hepatocellular carcinoma (HCC) are diagnosed each year, constituting 4.6% of all new human cancers. Objectives: The aim of our study is to study the recurrence and the 1 year, 3years and 5 years survival rate of HCC patients following Living Donor Liver Transplantation at Ain Shams Center for Organ Transplantation. Patients and Methods: This current study was conducted at Ain Shams Center for Organ Transplantation (ASCOT) who underwent Living donar liver Transplanation due to hepatitis C virus related hepatocellular carcinoma during the period starting from January 2008 and end in January 2019. A total number of 114 patients underwent LDLT due to HCV related hepatocellular carcinoma. Results: There was no statistically significant difference in overall survival time between patients within and beyond the Milan criteria. Infectious complications have become the most common source of morbidity and mortality following liver transplantation. Multiple organism infection is common as are concurrent infections by different infectious agents. Conclusion: Hepatocellular carcinoma (HCC) is a major health problem worldwide as more than 700, 000 cases are diagnosed yearly. The incidence of HCC is highest in Asia and Africa, where the endemic high prevalence of hepatitis B and hepatitis C strongly predisposes to the development of chronic liver disease and subsequent development of HCC.